Lobesity is developing a pharmaceutical agent to prevent obesity. The agent is initially targeting those patients with non-alcoholic fatty liver disease and hepatic steatosis.
Funding
Preclinical
Lobesity is developing a pharmaceutical agent to prevent obesity. The agent is initially targeting those patients with non-alcoholic fatty liver disease and hepatic steatosis.
Preclinical